Mounjaro is not a treatment for eating disorders. If you have been diagnosed with an eating disorder, discuss taking this medication with your medical providers. If you believe you have an eating disorder, please reach out to a qualified professional.
That said, GLP-1 receptor agonists have been shown to diminish binge eating.
“A plausible mechanism by which GLP-1 RA may induce weight loss is by suppressing appetite signalling in the brain and increasing satiety, leading to a reduced food intake [9, 10]. GLP-1 receptors are present in the central nervous system suggesting direct actions of GLP-1 in the brain [11]. GLP-1 infusions can enhance satiety and reduce energy intake in type 2 diabetes patients [12]. Furthermore, GLP-1 RA attenuates binge eating in obese patients [13], suggesting a role of GLP-1 RA in certain eating types.”
From: The change of Testosterone after weight intervention in obese men
September 2022
“Glucagon-like peptide-1 (GLP-1) is a hormone secreted from the small intestine in response to food ingestion. It can regulate food intake by slowing gastric emptying and through appetite inhibition in the brain thus reducing activation in appetite-related brain regions (possible brain areas involved: vagus nerve, nodose ganglia, hypothalamic nuclei, and the brain stem). Liraglutide, a GLP-1 receptor agonist, has been recently also approved for obesity management as an adjunct to physical activity and diet recommendations. It was previously approved in the type-2 diabetes treatment due to its effects associated with releasing insulin from the pancreas and decreasing glucagon release.”
Binge Eating Disorder: A 5-Year Retrospective Study on Experimental Drugs
Journal of Experimental Pharmacology, January 2021